CY1118711T1 - Συνδυασμος ( 3s, 3s' )4, 4'-δισουλφανοδιυλοδι (3-αμινοβουτανο 1-σουλφονικου οξεος) και ενος δευτερου αντιυπερτασικου παραγοντα - Google Patents

Συνδυασμος ( 3s, 3s' )4, 4'-δισουλφανοδιυλοδι (3-αμινοβουτανο 1-σουλφονικου οξεος) και ενος δευτερου αντιυπερτασικου παραγοντα

Info

Publication number
CY1118711T1
CY1118711T1 CY20171100303T CY171100303T CY1118711T1 CY 1118711 T1 CY1118711 T1 CY 1118711T1 CY 20171100303 T CY20171100303 T CY 20171100303T CY 171100303 T CY171100303 T CY 171100303T CY 1118711 T1 CY1118711 T1 CY 1118711T1
Authority
CY
Cyprus
Prior art keywords
combination
sulfonic acid
hypertenic
dissulfanodylylide
aminobutano
Prior art date
Application number
CY20171100303T
Other languages
Greek (el)
English (en)
Inventor
Catherine Llorens-Cortes
Yannick Marc
Ji Gao-Desliens
Fabrice Balavoine
Lionel Segard
Original Assignee
Quantum Genomics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Genomics filed Critical Quantum Genomics
Publication of CY1118711T1 publication Critical patent/CY1118711T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20171100303T 2011-12-21 2017-03-09 Συνδυασμος ( 3s, 3s' )4, 4'-δισουλφανοδιυλοδι (3-αμινοβουτανο 1-σουλφονικου οξεος) και ενος δευτερου αντιυπερτασικου παραγοντα CY1118711T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11306735 2011-12-21
PCT/EP2012/076607 WO2013092984A1 (en) 2011-12-21 2012-12-21 Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
EP12812987.1A EP2793878B1 (en) 2011-12-21 2012-12-21 Combination of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent

Publications (1)

Publication Number Publication Date
CY1118711T1 true CY1118711T1 (el) 2017-07-12

Family

ID=47522577

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100303T CY1118711T1 (el) 2011-12-21 2017-03-09 Συνδυασμος ( 3s, 3s' )4, 4'-δισουλφανοδιυλοδι (3-αμινοβουτανο 1-σουλφονικου οξεος) και ενος δευτερου αντιυπερτασικου παραγοντα

Country Status (25)

Country Link
US (1) US10959938B2 (https=)
EP (1) EP2793878B1 (https=)
JP (2) JP6212500B2 (https=)
KR (1) KR20140116879A (https=)
CN (2) CN104220062B (https=)
AU (1) AU2012356895B2 (https=)
BR (1) BR112014015276B1 (https=)
CA (1) CA2859704C (https=)
CY (1) CY1118711T1 (https=)
DK (1) DK2793878T3 (https=)
EA (1) EA028718B1 (https=)
ES (1) ES2619027T3 (https=)
HR (1) HRP20170267T1 (https=)
HU (1) HUE033403T2 (https=)
IL (1) IL233156B (https=)
IN (1) IN2014DN05787A (https=)
LT (1) LT2793878T (https=)
MX (1) MX345469B (https=)
PL (1) PL2793878T3 (https=)
PT (1) PT2793878T (https=)
RS (1) RS55774B1 (https=)
SI (1) SI2793878T1 (https=)
SM (1) SMT201700156T1 (https=)
WO (1) WO2013092984A1 (https=)
ZA (1) ZA201405266B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104220062B (zh) * 2011-12-21 2018-06-15 量子基因公司 (3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合
TW202207917A (zh) * 2020-05-06 2022-03-01 法商量子基因科技有限公司 包含腦胺肽酶抑制劑、利尿劑及全身性腎素-血管收縮素系統阻斷劑之醫藥組合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773712B1 (fr) * 1998-01-16 2000-06-02 Inst Nat Sante Rech Med Composition pharmaceutique comprenant au moins un inhibiteur de l'aminopeptidase a
PT1525188E (pt) * 2002-07-16 2008-10-16 Inst Nat Sante Rech Med Novos derivados de 4,4'-ditiobis-(3-aminobutano-1-sulfonatos) e composições que os contêm
FR2858617A1 (fr) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
US20080014187A1 (en) * 2006-07-15 2008-01-17 Bryant Villeponteau Compositions and Methods for Treating Hypertension and Inflammation
CN104220062B (zh) * 2011-12-21 2018-06-15 量子基因公司 (3s,3s’)4,4’-二硫烷二基双(3-氨基丁烷1-磺酸)和第二抗高血压药的组合

Also Published As

Publication number Publication date
CN104220062A (zh) 2014-12-17
SMT201700156T1 (it) 2017-05-08
IL233156A0 (en) 2014-07-31
PT2793878T (pt) 2017-03-23
AU2012356895A1 (en) 2014-07-31
CA2859704C (en) 2020-04-28
HRP20170267T1 (hr) 2017-05-19
LT2793878T (lt) 2017-05-25
BR112014015276B1 (pt) 2020-09-29
SI2793878T1 (sl) 2017-07-31
DK2793878T3 (en) 2017-03-27
BR112014015276A8 (pt) 2017-06-13
EA201400724A1 (ru) 2014-09-30
HUE033403T2 (en) 2017-11-28
MX2014007547A (es) 2014-08-01
NZ627251A (en) 2015-08-28
BR112014015276A2 (pt) 2017-06-13
JP2015506338A (ja) 2015-03-02
AU2012356895B2 (en) 2017-05-25
CN104220062B (zh) 2018-06-15
MX345469B (es) 2017-02-01
JP2017222696A (ja) 2017-12-21
JP6212500B2 (ja) 2017-10-11
EP2793878A1 (en) 2014-10-29
IN2014DN05787A (https=) 2015-05-15
RS55774B1 (sr) 2017-07-31
KR20140116879A (ko) 2014-10-06
ES2619027T3 (es) 2017-06-22
EP2793878B1 (en) 2017-02-01
IL233156B (en) 2018-05-31
CN109464432A (zh) 2019-03-15
US10959938B2 (en) 2021-03-30
WO2013092984A1 (en) 2013-06-27
EA028718B1 (ru) 2017-12-29
ZA201405266B (en) 2016-06-29
HK1203051A1 (en) 2015-10-16
CA2859704A1 (en) 2013-06-27
US20150320703A1 (en) 2015-11-12
PL2793878T3 (pl) 2017-08-31
JP6726138B2 (ja) 2020-07-22

Similar Documents

Publication Publication Date Title
CY1122182T1 (el) Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
CY1119252T1 (el) Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40
CY1122349T1 (el) Παραγωγα 1-benzyλ-3-υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των mcp-1, cxcr1 και ρ40
CY1119232T1 (el) Ενα διφαινυλοσουλφοναμιδιο ανταγωνιστης του υποδοχεα της ενδοθηλινης και της αγγειοτενσινης ii για τη θεραπεια της σπειραματοσκληρυνσης
CL2014000504A1 (es) Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
EA201170441A1 (ru) Терапевтические противовирусные пептиды
CL2013000104A1 (es) Compuestos derivados de heterociclicos nitrogenados sustituidos, agonistas del receptor ip; composicion farmaceutica; combinación farmaceutica; y uso para el tratamiento de la hipertension arterial pulmonar.
BR112016008849B8 (pt) Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
CY1120089T1 (el) Παραγωγα ουριας ή φαρμακολογικως αποδεκτα αλατα εξ' αυτων χρησιμα ως αγωνιστες του παρομοιου με υποδοχεα πεπτιδιου φορμυλιου 1(fprl-1)
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA200901583A1 (ru) N-(2-(гетарил)арил)арилсульфонамиды и n-(2-(гетарил)гетарил)арилсульфонамиды
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CY1118947T1 (el) Ασυμμετρες ουριες και ιατρικες χρησεις αυτων
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1113439T1 (el) Ενωση αζολιου
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
CL2010001362A1 (es) Forma de dosificacion farmaceutica para la liberacion inmediata de la sustancia activa 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato; y su uso para el tratamiento y/o prevencion de enfermedades oncologicas e inmunologicas, entre otras.
CY1113504T1 (el) Παραγωγο προπανο-1,3-διονης ή αλας αυτου